Boston Scientific Reports Q3 2026 Results Impacted by Cybersecurity Disruption and China Pricing Pressures
Boston Scientific (BSX) reported third-quarter revenue of $5.138 billion, representing a modest 1.5% year-over-year growth. However, adjusted earnings per share (EPS) fell to $0.73, missing the company's previous guidance range of $0.80 to $0.82. The results were significantly hampered by an eight-day operational disruption caused by a cybersecurity incident in August 2026, which reduced organic revenue growth by 300 basis points and negatively impacted gross margins. The company faces additional headwinds from the China market, where Volume-Based Procurement (VBP) initiatives have led to pricing erosion and volume declines in the Urology and Endoscopy segments. Looking ahead, management has revised its full-year 2026 organic revenue guidance downward to 3.75% growth and issued cautious outlooks for the fourth quarter due to inventory normalization and competitive pressures in the Electrophysiology franchise.
Topics: cybersecurity impact earnings miss guidance downgrade revenue growth segment performance
Read the full article at Motley Fool
Part of the story Boston Scientific Shares Fall After Cyberattack Impacts Sales and Earnings Guidance (2 articles)